R-CHOP-14 in patients with diffuse large B-cell lymphoma: Feasibility and preliminary efficacy

REFERENCES

• Ries L, Eisner M, Kosary C, Hankey B, Miller B, Clegg L, Mariotto A, Fay M, Feuer E, Edwards B. SEER Cancer Statistics Review, 1975–2000. National Cancer Institute; 2003.
   Google Scholar
• Gordon LI, Harrington D, Andersen J, Colgan J, Glick J, Nieman R, Mann R, Resnick GD, Barcos M, Gottlieb A, O'Connell M. Comparison of a second-generation combina-tion chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lym-phoma. N Engl J Med 1992;327:1342–1349.
   Google Scholar
• Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA Jr, Miller TP. Comparison of a standard regimen (CHOP) with three intensive che-motherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993;328:1002–1006.
   Google Scholar
• Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, Sonneveld P, Gisselbrecht C, Cahn JY, Harousseau JL et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995;333:1540–1545.
   Google Scholar
• Kewalramani T, Zelenetz AD, Hedrick EE, Donnelly GB, Hunte S, Priovolos AC, Qin J, Lyons NC, Yahalom J, Nimer SD, Maskowitz CH. High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis. Blood 2000;96:2399–2404.
   Google Scholar
• Vose JM, Zhang MJ, Rowlings PA, Lazarus HM, Bolwell BJ, Freytes CO, Pavlovsky S, Keating A, Yanes B, van Besien K et al. Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 2001;19:406–413.
   Google Scholar
• Moskowitz CH, Bertino JR, Glassman JR, Hedrick EE, Hunte S, Coady-Lyons N, Agus DB, Goy A, Jurcic J, Noy A et al. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobiliza-tion regimen for transplant-eligible patients with non-Hodgkin's lymphoma. J Chin Oncol 1999;17:3776–3785.
   Google Scholar
• Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235–242.
   Google Scholar
• Habermann T, Weller E, Morrison V, Cassileth P, Cohn J, Dakhil S, Gascoyne R, Woda B, Fisher R, Peterson B, Horning S. Phase III trial of rituximab-CHOP (R-CHOP) vs. CHOP with a second randomization to maintenance ritux-imab (MR) or observation in patients 60 years of age and older with diffuse large B-cell lymphoma (DLBCL). Blood 2003;102: a8.
   Google Scholar
• Pfreundschuh MG, Trumper L, Ma D, Osterborg A, Pettengell R, Trneny M, Shepherd L, Waleswski J, Zinzani P-L, Loeffler M. Randomized intergroup trial of first line treatment for patients 60 years with diffuse large B-cell non-Hodgkin's lymphoma (DLBCL) with a CHOP-like regimen with or without the anti-CD20 antibody rituximab - early stopping after the first interim analysis. J Chin Oncol (Meeting Abstracts) 2004;22: 6500.
   Google Scholar
• Pfreundschuh M, Tramper L, Kloess M, Schmits R, Feller AC, Rube C, Rudolph C, Reiser M, Hossfeld DK, Eimerma-cher H et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 2004;104:634–641.
   Google Scholar
• Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-Lopez A, Hagenbeek A et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Spon-sored International Working Group. J Chin Oncol 1999;17:1244.
   Google Scholar
• Hotta T, Shimakura Y, Ishizuka N, Fukuda H, Itoh K, Morishima Y, Suzuki T, Ueda R, Shimoyama M, Tobinai K et al. Randomized phase III study of standard CHOP (S-CHOP) versus biweekly CHOP (Bi-CHOP) in aggressive non-Hodgkin's lymphoma (NHL): Japan Clinical Oncology Group Study, JCOG 9809. J Chin Oncol (Meeting Abstracts) 2003;22:565.
   Google Scholar
• Blayney DW, LeBlanc ML, Grogan T, Blayney DW, LeBlanc ML, Grogan T, Gaynor ER, Chapman RA, Spiridonidis CH, Taylor SA, Bearman SI, Miller TP, Fisher RI. Dose-intense chemotherapy every 2 weeks with dose-intense cyclopho-sphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349). J Chin Oncol 2003;21: 2466–2473.
   Google Scholar
• Shipp M, Neuberg D, Janicek M, Canellos G, Shulman L. High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin's lymphoma: a dose-find-ing pilot study. J Chin Oncol 1995;13:2916–2923.
   Google Scholar